semaglutide glp 1 for weight loss Decoding GLP-1 Medications Another Weight-Loss Trial Win for

doi: 10.1111/j.1460-9568.1995.tb00650.x

Preclinical studies have identified that GLP-1 analogs such as exendin-4 and GLP-1RAs have direct anti-atherosclerotic and anti-inflammatory effects that may contribute to their cardio- and neuroprotective nature.[42] GLP-1RAs can also directly interact with cardiomyocytes, inducing receptor-mediated ischemic conditioning that decreases myocardial infarct size in test animals receiving GLP-1RAs.[43] Similar effects were noted in rodent brains, with liraglutide reducing cerebral infarct volume in rats.[42] Randomized clinical trials (RCTs) also identified that exenatide similarly reduced myocardial infarct size and liraglutide reduced the resulting necrotic area in human patients following a MI.[43] This may account for the reduced need for coronary revascularization in patients on GLP-1RAs.[12] Despite the findings of overall improvements to composite cardiovascular outcomes, GLP-1RAs showed a non-significant trend toward reducing MI risk and did not affect rates of hospitalization for unstable angina in patients with diabetes.[12] These agents tend to have a stronger effect on stroke reduction in such patients, highlighting the complexity and variability of cardiovascular disease and its sequelae

Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease

This is part of your learning curve on the GLP-1 therapy beginner guide

Scientific Session

52 The trial aims to enroll 20 participants to analyze proximal tubular natriuresis with combination therapy and monotherapy as primary outcomes, and measured glomerular filtration rate, eGFR, and urinary albumin excretion as secondary outcomes